Product Code: GVR-4-68039-973-0
MRI Contrast Media Agents Market Growth & Trends:
The global MRI contrast media agents market size is expected to reach USD 3.14 billion by 2030, registering a CAGR of 5.8% from 2022 to 2030, according to a new report by Grand View Research, Inc. The factors anticipated to propel market growth include the rising prevalence of chronic diseases and the increasing demand for early diagnostic methods. Additionally, the industry is expanding since less intrusive techniques are increasingly being used. Further, it is anticipated that the increasing number of clinical trials to determine the efficacy and efficiency of MRI contrast media agents in various clinical applications will spur market expansion. According to data from the Organization for Economic Co-operation and Development (OECD), the U.S. did the most MRI scans per 1,000 people in the world in 2018. In the U.S., the number of MRI scans performed increased by roughly 1.08%, or from 109.5 per 1000 people in 2014 to 118.9 per 1000 people in 2018.
MRI contrast agents are being increasingly used in the diagnosis of chronic diseases using MRI technology. According to the WHO, chronic diseases will account for three-quarters of all deaths worldwide by 2020. The prevention of chronic diseases is possible if patients are diagnosed and treated early. However, to date, only four companies: Bayer AG, GE Healthcare LLC, Guerbet GmbH, and Bracco Imaging SpA are actively involved in the manufacturing of MRI contrast agents globally, which will create some tremendous opportunities for small businesses as well as the leading organizations.
Companies such as Miltenyi Biotec B.V. & Co. Kg and Reveal Pharma have their contrast media under the preclinical trial stage. The efficacy, safety, and in vivo compatibility of contrast agents make it critical for receiving FDA approval. Several government initiatives to develop modern healthcare centers and provide financial support for new MRI machines are driving the market. However, the reduction in diagnostic scans during the COVID-19 pandemic, disruption in logistics, and halt in the development of generic products led to a decline in the market in 2020 and 2021. It is expected to bounce back by late 2022.
MRI Contrast Media Agents Market Report Highlights:
- Adoption of advanced imaging technologies is augmenting the growth of the market
- The paramagnetic agents product segment is anticipated to be the fastest-growing segment during the forecast period due to its efficiency and wide adoption of these agents by radiologists
- By application, neurological imaging dominated the market in 2021 largely due to growing number of neurological conditions and increasing demand for less invasive diagnostic procedures
- The hospitals end-use segment accounted for the largest share in 2021 due to the treatment of chronic illnesses in the hospitals and high financial support
- The clinical type segment accounted for the largest share in 2021 as numerous clinical research is being carried out for quicker FDA approvals
- In 2021, North America dominated the global market owing to continuous research and high adoption of advanced techniques in the region
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation & Scope
- 1.1.1 Product
- 1.1.2 Type
- 1.1.3 Application
- 1.1.4 End-use
- 1.1.5 Regional Scope
- 1.1.6 Estimates and Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details of Primary Research
- 1.3.5.1 Data for primary interviews in North America
- 1.3.5.3 Data for Primary Interviews in Europe
- 1.3.5.4 Data for Primary Interviews in Europe
- 1.3.5.6 Data for Primary Interviews in Rest of the world
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis (Model 1)
- 1.6.1.1 Approach 1: Commodity Flow Approach
- 1.6.2 Volume Price Analysis (Model 2)
- 1.6.2.1 Approach 2: Volume Price Analysis
- 1.7 List of Secondary Sources
- 1.8 Objectives
- 1.8.1 Objective 1
- 1.8.2 Objective 2
Chapter 2 Executive Summary
- 2.1 Market Outlook
- 2.2 Segment Outlook
- 2.2.1 Product Outlook
- 2.2.2 Type Outlook
- 2.2.3 Application Outlook
- 2.2.4 End-use Outlook
- 2.2.5 Regional Outlook
- 2.3 Competitive Insights
Chapter 3 Market Variables, Trends & Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent market outlook
- 3.2 Penetration & Growth Prospect Mapping
- 3.2.1 Reimbursement framework
- 3.3 Market Dynamics
- 3.3.1 Market Driver Analysis
- 3.3.1.1 Rising patient population
- 3.3.1.2 Technological advancement
- 3.3.1.3 Increasing awareness regarding early diagnosis
- 3.3.2 Market Restraint Analysis
- 3.3.2.1 High cost of MRI contrast media agents
- 3.4 MRI Contrast Media Agents Market Analysis Tools
- 3.4.1 Industry Analysis - Porter's
- 3.4.1.1 Supplier Power
- 3.4.1.2 Buyer Power
- 3.4.1.3 Substitution Threat
- 3.4.1.4 Threat from new entrant
- 3.4.1.5 Competitive rivalry
- 3.4.2 PESTEL Analysis
- 3.4.2.1 Political Landscape
- 3.4.2.2 Technological Landscape
- 3.4.2.3 Economic Landscape
- 3.4.3 Major Deals & Strategic Alliances Analysis
- 3.4.4 Market Entry Strategies
Chapter 4 Product Business Analysis
- 4.1 Definitions and Scope
- 4.1.1 Paramagnetic agents
- 4.1.2 Superparamagnetic agents
- 4.2 Product Market Share Analysis
- 4.3 Segment Dashboard
- 4.4 Global MRI Contrast Media Agents Market by Product
- 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.6 Paramagnetic agents
- 4.6.1 Paramagnetic agents Market Estimates And Forecast, 2018 - 2030
- 4.7 Superparamagnetic agents
- 4.7.1 Superparamagnetic agents Market Estimates And Forecast, 2018 - 2030
Chapter 5 Type Business Analysis
- 5.1 Definitions and Scope
- 5.1.1 Clinical
- 5.1.2 Preclinical
- 5.2 Type Market Share Analysis
- 5.3 Segment Dashboard
- 5.4 Global MRI Contrast Media Agents Market by Type
- 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5.1 Clinical
- 5.5.1.1 Clinical Market Estimates And Forecast, 2018 - 2030
- 5.5.2 Preclinical
- 5.5.2.1 Preclinical Market Estimates and Forecast, 2018 - 2030
Chapter 6 Application Business Analysis
- 6.1 Definitions and Scope
- 6.1.1 Gastrointestinal
- 6.1.3 Intravenous
- 6.1.4 Hepatobiliary
- 6.1.5 Neurologicla Imaging
- 6.1.6 Others
- 6.2 Application Market Share Analysis
- 6.3 Segment Dashboard
- 6.4 Global MRI Contrast Media Agents Market by Application
- 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5.1 Gastrointestinal
- 6.5.1.1 Gastrointestinal Market Estimates And Forecast, 2018 - 2030
- 6.5.2 Intravenous
- 6.5.2.1 Intravenous Market Estimates And Forecast, 2018 - 2030
- 6.5.3 Hepatobiliary
- 6.5.3.1 Hepatobiliary Market Estimates and Forecast, 2018 - 2030
- 6.5.4 Neurological Imaging
- 6.5.4.1 Neurological Imaging Market Estimates and Forecast, 2018 - 2030
- 6.5.5 Others
- 6.5.5.1 Others Market Estimates and Forecast, 2018 - 2030
Chapter 7 End-use Business Analysis
- 7.1 Definitions and Scope
- 7.2 Type Market Share Analysis
- 7.3 Segment Dashboard
- 7.4 Global MRI Contrast Media Agents Market by End-use
- 7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.5.1 Hospitals
- 7.5.1.1 Hospitals Market Estimates And Forecast, 2018 - 2030
- 7.5.2 Imaging centers
- 7.5.2.1 Imaging centers Market Estimates and Forecast, 2018 - 2030
Chapter 8 MRI Contrast Media Agents Market: Regional Market Analysis, 2018 - 2030 (Value) (USD Million)
- 8.1 Regional market share analysis, 2021 & 2030
- 8.2 Regional Market Dashboard
- 8.3 Global Regional Market Snapshot
- 8.4 Regional Market Share and Leading Players
- 8.4.1 North America
- 8.4.2 Europe
- 8.4.3 Asia Pacific
- 8.4.4 Latin America
- 8.4.5 Middle East & Africa
- 8.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
- 8.5.1 North America
- 8.5.2 Europe
- 8.5.3 Asia Pacific
- 8.5.4 Latin America
- 8.5.5 Middle East & Africa
- 8.6 Market Size, & Forecasts and Trend Analysis, 2021 to 2030:
- 8.7 North America
- 8.7.1 Market estimates and forecast, 2018 - 2030
- 8.7.2 U.S.
- 8.7.2.1 U.S. market estimates and forecast, 2018 - 2030
- 8.7.3 Canada
- 8.7.3.1 Canada market estimates and forecast, 2018 - 2030
- 8.8 Europe
- 8.8.1 Europe. market estimates and forecast, 2018 - 2030
- 8.8.2 Germany
- 8.8.2.1 Germany market estimates and forecast, 2018 - 2030
- 8.8.3 U.K.
- 8.8.3.1 U.K. market estimates and forecast, 2018 - 2030
- 8.8.4 France
- 8.8.4.1 France market estimates and forecast, 2018 - 2030
- 8.8.5 Italy
- 8.8.5.1 Italy market estimates and forecast, 2018 - 2030
- 8.8.6 Spain
- 8.8.6.1 Spain market estimates and forecast, 2018 - 2030
- 8.9 Asia Pacific
- 8.9.1 Asia Pacific market estimates and forecast, 2018 - 2030
- 8.9.2 China
- 8.9.2.1 Market estimates and forecast, 2018 - 2030
- 8.9.3 Japan
- 8.9.3.1 Japan market estimates and forecast, 2018 - 2030
- 8.9.4 India
- 8.9.4.1 India. market estimates and forecast, 2018 - 2030
- 8.9.5 South Korea
- 8.9.5.1 Market estimates and forecast, 2018 - 2030
- 8.10 Latin America
- 8.10.1 Latin America market estimates and forecast, 2018 - 2030
- 8.10.2 Brazil
- 8.10.2.1 Brazil market estimates and forecast, 2018 - 2030
- 8.10.3 Mexico
- 8.10.3.1 Market estimates and forecast, 2018 - 2030
- 8.10.4 Argentina
- 8.11 Middle East and Africa
- 8.11.1 Market estimates and forecast, 2018 - 2030
- 8.11.2 South Africa
- 8.11.2.1 South Africa market estimates and forecast, 2018 - 2030
- 8.11.3 Saudi Arabia
- 8.11.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030
- 8.11.4 UAE
- 8.11.4.1 UAE market estimates and forecast, 2018 - 2030
Chapter 9 MRI Contrast Media Agents Market: Competitive Market Analysis,
- 9.1 Recent Developments & Impact Analysis, By Key Market Participants
- 9.2 Company/Competition Categorization
- 9.3 Vendor Landscape
- 9.3.1 List of Key Distributors and Channel Partners
- 9.3.2 Key customers
- 9.3.3 Key company market share analysis, 2021
- 9.3.4 Bayer AG
- 9.3.5 General Electric Company
- 9.3.6 Guerbet GmbH
- 9.3.7 Bracco Diagnostic, Inc.
- 9.3.8 Nano Therapeutics Pvt. Ltd.
- 9.3.9 Lantheus Medical Imaging, Inc.
- 9.3.10 iMax
- 9.3.11 Trivitron Healthcare